Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 6;8:8676. doi: 10.1038/s41598-018-26999-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The reduction effect of lobohedleolide on C/EBP transcription factor activity. Ava5 cells were cotransfected with 0.2 μg of pCMV-Rellina-Luc and (a) pNF-κB-Luc, (b) pC/EBP-Luc, or (c) pAP-1-Luc constructs for 6 h, and the transfected cells were treated with lobohedleolide at the indicated concentrations for 3 days. Cell lysates were subjected to luciferase activity assay. (d) Schematic diagram of the COX-2 and mutagenized C/EBP of COX-2 promoter constructs. (e) The inhibitory effect of lobohedleolide on COX-2 promoter activity was reduced by mutagenized C/EBP on COX-2 promoter. Ava5 cells were transfected with pCOX-2-Luc or pCOX-2-(m/C/EBP)-Luc for 6 h, and the transfected cells were treated with lobohedleolide at indicated concentrations for 3 days. Cell lysates were subjected to luciferase activity assay. Data are presented as mean ± SD of at least three independent experiments, with each measurement carried out in triplicate. Asterisks indicate significant difference between lobohedleolide- and DMSO-treated Ava5 cells. *P < 0.05; **P < 0.01.